Biotech News

Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access

Humacyte (HUMA)HumacyteFDA / regulatory

–sBLA submission seeks to add arteriovenous access for hemodialysis as second approved indication for the ATEV. –sBLA supported by results from three Phase 3 studies in hemodialysis access. –“For too long, patients on dialysis, and women in particular, have had to settle for access options that

Related news

Humacyte

Bioengineered Human Tissue Platform Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale. SYMVESS SYMVESS is an FDA-approved acellular tissue-engineered...

Recent company news

Stock data

Close
0.54 USD
Market cap
308.61M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States